160 likes | 236 Views
WP 5: Secure access. C. Ohmann (chair), K. Kuhn ( co -chair). Aim of the presentation. partners objectives description of work deliverables milestones interactions next steps. Objective.
E N D
WP 5: Secure access C. Ohmann (chair), K. Kuhn (co-chair) BioMedBridges Kick-off Meeting 5-6 March 2012, Hinxton, Cambridge
Aim of the presentation • partners • objectives • description of work • deliverables • milestones • interactions • next steps
Objective WP5 will establish a security framework which is compliant with legal and ethical requirements on the national and European level. It will both use security policies compliant with European regulations, and take into account policies and consent and use agreements of the participating infrastructures. For implementation of authentication and authorization services, existing standards, solutions, and concepts of European e-Infrastructures will be used in adequate way.
WP-members (preliminary) • C. Ohmann (Heinrich-Heine-Universitaet Düsseldorf, Germany, partner 5) • K. Kuhn (Klinikum Rechts der Isar der TU München, Germany, partner 7) • J. Ellenberg, D. Arendt, A. Keppler, A. Brazma (European Molecular Biology Laboratory, UK, partner 1) • A. Pollex-Krüger (Technologische und Methodenplattform für die vernetzte Forschung e.V. , Germany, partner 10) • M. Winn (Science and Technology Facilities Council, UK, partner 4) • M. Hrabé, C. Lengger, M. Räß, R. Ludwig, R. Frank (Helmholtz Zentrum Muenchen, Deutsches Forschungszentrum fuer Gesundheit und Umwelt GmbH, Germany, partner 11) • S. Klein, W. Niessen (Erasmus Universitair Medisch Centrum Rotterdam, • Netherlands, partner 9) • NN (Forschungsverbund Berlin e.V., Germany, partner 6) • H. Raoul, C. Carbonelle (Institut National de la Santé et de la Recherche Médicale, France, partner 14)
WP5 tasks WT1-4: Regulations, requirements and design aspects WT5-8: Security implementation
Interaction • Strong interaction with other WPs from the beginning, especially WP3,4 and 5 and the use cases (WP6-WP10) • Close link to the BMS infrastructures via the partners involved (BBMRI, EATRIS, ECRIN, ELIXIR, Infrafrontier, INSTRUCT, EMBRC, ERINHA, EU-Openscreen, Euro-Bioimaging) • Interaction with other EU-projects in order to learn from existing/ongoing activities (e.g. Transform, p-medicine, EHR4CR)
Next steps • identification of WP-members from the participating partners • regular telephone conferences of WP 5 (at least every 4 weeks) • face-to-face meeting of WP 5 (e.g. June 2012) • in the first half year of 2012 concentration on • - WT1 • - WT3.1 • - WT3.2 • - WT3.3
WP5Questions for the dialogue between use cases and infrastructures What can be shared What are the categories of available data Genetic, omics Clinical: diagnoses, med histories, medication What does the legal and/or contractual situation allow? Open / anonymous / derived data? informed consent available? Access restrictions? What is the technical basis offered See WP4: browsing, programmatic access, RDF What is needed, what is the purpose individual data (anonymized?) vs summaries/derived data How will data be aggregated? Are access tiers needed, e.g. for members only?